Joshua Samis

Overview

Joshua Samis concentrates his practice in matters concerning corporate finance and private equity. He represents private equity sponsors, public and private companies and commercial lending institutions in connection with the negotiation and documentation of domestic and cross-border transactional matters, including credit facilities related to leveraged acquisitions, recapitalizations, and loan workouts and restructurings. Josh’s expansive knowledge in corporate finance and private equity makes him an asset to our lawyers across various practices and offices. Josh is also a current member of the Firm’s Income Partner Compensation Committee and Technology Committee.

Results

Represented a variety private equity groups and their portfolio companies in connection with negotiation of debt commitment letters and credit facilities for the purposes of funding acquisitions, including senior secured credit facilities, secured second-lien credit facilities, bridge debt facilities and mezzanine debt facilities
Represented Amulet Capital Partners in a variety of transactions including its investments in US Fertility through the acquisition of IntegraMed and Shady Grove Fertility as well as investments in Children’s Choice Dental Management and United Vein & Vascular Centers
Represented Blue Sea Capital in a variety of transactions including its investments in Apex Physics Partners, Beacon Oral Specialists, SignatureMD, Specialty Smile Partners, Spectrum Vision Partners, and WillowWood Global

Represented Comvest Partners in a variety of transactions including its investments in Engage2Excel and Spinrite LP
Represented Gemspring Capital Management, LLC, in a variety of transactions including its investments in Zavation Medical Products
Represented H.I.G. Capital, in a variety of transactions including its investments in BioVectra, Lipari Foods, Reliant Rehabilitation, Valtris Specialty Chemicals, and VIP Cinema Holdings
Represented Martis Capital Management in a in a variety of transactions including its investments in DCN Dx and WellHaven PetHealth
Represented NMS Capital in a variety of transactions including its investments in Flourish Research, Strive Medical and U.S. Urology Partners
Represented Pouschine Cook Capital Management in a variety of transactions including its investments in Curexa Pharmacy, Griswold Home Care, and Southern Dental Alliance
Represented Quad-C Management in its investments in a variety of transactions including its investments in Prism Vision Group and US Endo Partners
Represented Revelstoke Capital Partners in a variety of transactions including its recapitalization of Fast Pace Urgent Care and its acquisition of Monte Nido
Represented Sheridan Capital in a variety of transactions including its investments in ADVI Health, DAS Health, Oral Surgery Partners, SimiTree Healthcare and Tarrytown Expocare Pharmacy
Represented The Sterling Group in a variety of transactions including its investments in Gulf Winds, West Star Aviation, its formation of Fencing Supply Group (including in connection with the acquisitions of Merchants Metals and Binford Supply Fencing Supply Group), the recapitalization of Tangent Technologies, and the business combination of Construction Supply Group with White Cap, a business of HD Supply
Represented WindRose Health Investors, LLC, in a variety of transactions including its investments in BPD, Bluestone Physician Services, Caregiver, Healthmap, Kolmac Clinic, Lykan Biosciences, Medical Knowledge Group, RevHealth, StateServ, Traditions Behavioral Health, Trumpet Behavioral Health, Veristat, and Workplace Options
Represented a leading hedge fund as a lender to several market leading national cannabis companies
Represented Quorum Health Corporation in its pre-packaged Chapter 11 cases involving the restructuring of approximately $1.5 billion of funded debt. The successful restructuring took place during the Covid-19 pandemic and ultimately resulted in the successful deleveraging of Quorum’s balance sheet by approximately $500 million.
Represented Energy Future Holdings in its Chapter 11 restructuring*
Represented GTCR in connection with a variety of investments, including with its investment in Cord Blood Registry and subsequent $700 million sale to AMAG Pharmaceuticals, Inc.*
Represented Madison Dearborn Partners in connection with a variety of investments, including in connection with its $7.3 billion take-private acquisition of CDW Corporation*
Represented Summit Partners in connection with a variety of investments, including its investments in Empower RF Systems, FineLine Technologies, HealthSun, Morphe, Perforce Software, and Salient Partners*
Represented Sun Capital Partners in connection with a variety of investments, including its investments in Flavor 1st, Garden Fresh Restaurant, Kellwood Company, and LOUD Technologies*